Shares of AstraZeneca (NASDAQ: AZN) were on an upswing in pre-market trading on Friday as its investigational drug danicopan (ALXN2040) showed positive results in an ALPHA Phase III trial. Danicopan (ALXN2040) is an investigational, oral factor D inhibitor that showed positive high-level results in patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is an acquired, rare life-threatening disease of the blood which causes the destruction of red blood cells. The interim Phase 3 ALPHA trial indicated that Danicopan plus Ultomiris or Soliris met its primary endpoint with "statistically significant and clinically meaningful improvements in haemoglobin levels, transfusion avoidance and FACIT [ Functional Assessment of Chronic Illness Therapy] Fatigue scores from baseline.
https://www.tipranks.com/news/astrazeneca-nasdaq-azn-up-on-positive-clinical-data-and-evusheld-approval?utm_source=advfn.com&utm_medium=referral